MarketCap
Facebook
X
TelegramAnnual report 2023
added 03-15-2024
Brickell Biotech Market Cap 2011-2026 | BBI
As of March 02, 2026 Brickell Biotech has a market cap of $ 6.06 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Brickell Biotech
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.4 M | 5.93 M | 375 K | 30.4 M | 4.69 M | 21.4 M | 19.1 M | 21.8 M | 32.1 M | 92.3 M | 120 M | 307 M | 255 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 307 M | 375 K | 70.9 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alector
ALEC
|
247 M | $ 2.11 | -13.17 % | $ 217 M |  USA |
 |
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
2.77 B | $ 20.52 | -2.12 % | $ 2.59 B | USA |
 |
I-Mab
IMAB
|
127 M | - | - | $ 866 M |  China |
 |
Axsome Therapeutics
AXSM
|
8.67 B | $ 164.13 | 0.15 % | $ 8.17 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aytu BioScience
AYTU
|
15.8 M | $ 2.49 | -3.11 % | $ 15.6 M | USA |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
BridgeBio Pharma
BBIO
|
13.1 B | $ 64.24 | -3.37 % | $ 12.3 B | USA |
 |
BioAtla
BCAB
|
144 M | $ 0.18 | -26.92 % | $ 8.6 M | USA |
 |
BioCardia
BCDA
|
8.9 M | $ 1.37 | 6.2 % | $ 29 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
1.72 B | $ 8.61 | -1.66 % | $ 1.78 B | USA |
 |
Black Diamond Therapeutics
BDTX
|
104 M | $ 2.4 | -3.04 % | $ 132 M | USA |
 |
Beam Therapeutics
BEAM
|
3.2 B | $ 28.29 | -0.6 % | $ 2.8 B | USA |
 |
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
8.59 B | $ 11.47 | -0.43 % | $ 742 M | USA |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Biogen
BIIB
|
29.4 B | $ 187.68 | -2.16 % | $ 27.5 B | USA |
 |
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | USA |
 |
BioVie
BIVI
|
2.44 M | $ 1.38 | -0.01 % | $ 2.04 M | USA |
 |
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
71.4 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
38.2 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
49 M | - | 4.14 % | $ 49.1 M | USA |
 |
BioLineRx Ltd.
BLRX
|
1.35 B | $ 2.91 | 2.83 % | $ 908 M |  Israel |
 |
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
11.7 B | $ 60.68 | -1.7 % | $ 11.6 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
122 B | $ 62.54 | 0.27 % | $ 127 B | USA |
 |
Benitec Biopharma
BNTC
|
556 M | $ 10.85 | -0.5 % | $ 447 M | USA |
 |
BioNTech SE
BNTX
|
62.9 B | $ 109.85 | -0.34 % | $ 27.2 B | Germany |
 |
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M | Canada |
 |
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | USA |
 |
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | USA |
 |
BioXcel Therapeutics
BTAI
|
5.37 M | $ 1.63 | -2.69 % | $ 4.13 M | USA |
 |
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
9.48 M | - | -39.0 % | $ 4.57 M | USA |
 |
Burford Capital Limited
BUR
|
2.09 B | $ 8.6 | 1.9 % | $ 1.39 B | Britain |
 |
Athira Pharma
ATHA
|
16.2 M | - | - | $ 269 M | USA |